Side-by-side · Research reference

AOD-9604vsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed10/47 cited

BHuman-MechanisticDraft8/37 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2008

~30 minHalf-life

SQ · Abdomen · Daily fasted

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

AOD-9604

Epitalon

Primary target

β3-adrenergic receptor (proposed)Ng 2008

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

No GH-axis or IGF-1 feedback

—

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

Epitalon

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Frequency

Once daily, fasted

Once daily during a cycle

Lower / starter dose

150 mcg / day

2.5 mg / day

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2008

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Duration

8–12 weeks per cycle

10–20 day cycles, 1–2× per year

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

Bacteriostatic water

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

Pre-sleep preferred (pineal alignment)

Half-life

~30 min plasma

Hours (estimated)

04Side Effects & Safety

Parameter

AOD-9604

Epitalon

Injection site reaction

Mild erythema

Mild irritation

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

Theoretical via telomerase activation in pre-malignant cells

Pregnancy / OB

Avoid

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Long-term safety

—

Limited Western RCT data

Antibody formation

—

Not reported

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

AOD-9604

Epitalon

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Injection site

SQ — abdomen preferred. Rotate sites.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Pre-sleep preferred to align with pineal axis.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

Epitalon

— no documented stacks